Original ContributionUtility of Integrated Computed Tomography—Positron Emission Tomography for Selection of Operable Malignant Pleural Mesothelioma
References (26)
Natural history and epidemiology of malignant mesothelioma
Chest
(1993)Current approach to malignant mesothelioma of the pleura
Chest
(1995)- et al.
Multimodality treatment of diffuse malignant pleural mesothelioma
Semin Oncol
(2002) - et al.
Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma
Ann Oncol
(2007) - et al.
Surgical treatment of malignant pleural mesothelioma: a review
Chest
(2003) - et al.
The role of computed tomography scanning in the initial assessment and follow-up of malignant pleural mesothelioma
J Thorac Cardiovasc Surg
(1988) - et al.
Metabolic imaging of malignant pleural mesothelioma with fluorodeoxyglucose positron emission tomography
Chest
(1998) - et al.
Integrated computed tomographypositron emission tomography in patients with potentially resectable malignant pleural mesothelioma: staging implications
J Thorac Cardiovasc Surg
(2005) - et al.
Positron emission tomography predicts survival in malignant pleural mesothelioma
J Thorac Cardiovasc Surg
(2006) The role of PET in the surgical management of malignant pleural mesothelioma
Lung Cancer
(2005)
Positron emission tomography with F18-Flourodeoxyglucose in the staging and preoperative evaluation of malignant pleural mesothelioma
J Thorac Cardiovasc Surg
Mesothelioma: benefit from surgical resection is questionable
J Thorac Oncol
Mesothelioma trends in the United States: an update based on surveillance, epidemiology and end results program data for 1973 through 2003
Am J Epidemiol
Cited by (49)
FDG PET/CT for Staging and Restaging Malignant Mesothelioma
2022, Seminars in Nuclear MedicineCitation Excerpt :However, the fact that PET/CT relies on functional/metabolic information rather than appearance, determines the major advantage of the modality with respect to morphological imaging, since typical CT findings consisting in pleural nodules, pleural thickening with or without lung encasing, can be highly sensitive (sensitivity 94%-100%), but tend to be poorly specific for MPM (specificity 36%-51%).3,16,42 This advantage of metabolic imaging with [18F]FDG PET/CT determines also its ability to better stage MPM (Fig. 1), leading to a direct impact on patients management16 ranging from 20% to 40% of the cases.43-46 In fact, various authors have reported a significantly superior diagnostic performance for PET/CT compared to CT alone,46-48 particularly for diffuse chest disease, mediastinal lymph nodes and extra-thoracic localizations, for which the modality shows sensitivities of 100%, 88%, and 100%, respectively (Table 2).
FDG PET/CT for Primary Staging of Lung Cancer and Mesothelioma
2022, Seminars in Nuclear MedicineCitation Excerpt :NCCN guidelines recommend 18F FDG PET/CT prior to surgery in clinical stage 1-3A and epithelioid histology. 18F FDG PET/CT may identify locally advanced tumor, nodal metastases, or extrathoracic metastases, precluding surgery.28 In a study by Erasmus et al 18F-FDG PET/CT precluded surgery in 41% of patients.29
Pleural Tumors
2022, Oncologic Imaging: A Multidisciplinary ApproachThe role of imaging in malignant pleural mesothelioma: an update after the 2018 BTS guidelines
2020, Clinical RadiologyCitation Excerpt :Further, identifying mediastinal nodes on CT is difficult (sensitivity 60% and specificity 70%) as adjacent pleural thickening obscures the lymphadenopathy.4,29,34,68 PET/CT performs better for the detection of nodal disease,69 but the reference standard for staging mesothelioma remains postoperative histological staging and mediastinoscopic sampling of lymph nodes. CT TNM staging is associated with interobserver variability making it is suboptimal in predicting prognosis in patients with MPM.70,71
Diseases of the Pleura and Mediastinum
2019, Abeloff’s Clinical OncologyUncommon Thoracic Tumors
2015, Clinical Radiation Oncology
This article might include the discussion of investigational and/or unlabeled uses of drugs and/or devices that might not be approved by the FDA.
Electronic forwarding or copying is a violation of US and international copyright laws.
Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by CIG Media Group, LP, ISSN #1525-7304, provided the appropriate fee is paid directly to Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923 USA. www.copyright.com 978-750-8400.
Abstract accepted for poster presentation at the American Thoracic Society International Conference in Toronto, Ontario, Canada, in May 2008.